January 26, 2023 Life Science Tools Product Launch Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant Read more
January 19, 2023 Bio/Pharma/CRO [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial Read more
January 12, 2023 Uncategorized Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above Read more
January 6, 2023 Acad, Gov/Utilities FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma Read more
December 23, 2022 Acad, Gov/Utilities FDA approves Roche’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma Read more
December 21, 2022 Acad, Gov/Utilities Clinical Research/Diagn. Microscopy FDA approves Roche’s Actemra for the treatment of COVID-19 in hospitalised adults Read more
December 14, 2022 M&A, Partnerships Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options Read more
December 12, 2022 Product Launch Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma Read more
December 12, 2022 Product Launch Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022 Read more
December 12, 2022 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Roche: Changes in the Board of Directors and the Corporate Executive Committee Read more
